Market Pulse

Event summary

• Viz.ai appointed Jallel Harrati as Chief Revenue Officer (CRO), effective immediately.
• Harrati previously served as SVP and GM of New Business Development at Suki.
• Viz.ai has deployed its platform in 2,000 hospitals across the United States.
• Viz Assist, Viz.ai’s multimodal AI agent platform, aims to assist clinicians with tasks like chart summaries and coding recommendations.

The big picture

What we're watching

Execution Risk

Harrati’s success hinges on integrating his experience scaling commercial organizations with Viz.ai’s existing culture and sales processes, particularly given his background at a competitor.

Market Dynamics

The adoption rate of Viz Assist will be a key indicator of whether clinicians find the AI agent platform genuinely valuable and integrates into their workflows, or if it becomes another unused enterprise tool.

Competitive Landscape

The competitive pressure from companies like Suki and others in the AI-driven clinical solutions space will likely intensify as Viz.ai attempts to expand its market share and solidify its position as a category leader.

Event summary

• Toast and Instacart have formed a strategic partnership to streamline operations for restaurants and retailers in the U.S.
• Retailers using Toast will gain simplified onboarding to the Instacart Marketplace.
• Restaurants will have access to Instacart Business for same-day delivery of essential supplies.
• Pilot programs are planned for early 2026, with full rollout expected later in the year.
• The partnership leverages Toast’s SKU data and Instacart’s catalog attribution workflows.

The big picture

What we're watching

Integration Speed

The success of this partnership hinges on the speed and ease with which Toast’s retail and restaurant customers can integrate with the Instacart Marketplace, potentially impacting adoption rates.

Margin Impact

The cost of Instacart Business’s same-day delivery services could compress restaurant margins if not managed effectively, requiring Toast to demonstrate clear value to its customers.

Competitive Response

Other restaurant technology providers will likely observe this partnership and may seek to develop competing offerings, potentially intensifying competition in the digital hospitality space.

Event summary

• Brandon Satoren will become CFO and Corporate Secretary of Mount Logan Capital Inc. on April 1, 2026.
• Current CFO Nikita Klassen will remain with the company through March 31, 2026.
• Satoren currently holds similar roles across Mount Logan’s retail credit platform, including BCP Investment Corporation.
• Mount Logan Capital Inc. manages over $2.1 billion in assets under management as of September 30, 2025.
• The change follows a business combination with 180 Degree Capital and a Nasdaq listing.

The big picture

What we're watching

Execution Risk

Satoren’s appointment suggests a focus on integrating the 180 Degree Capital acquisition; the success of this integration will hinge on his ability to streamline operations and realize synergies.

Governance Dynamics

The rapid succession of CFOs, while framed as strategic, could indicate underlying governance challenges or a desire to accelerate the integration process.

Financial Performance

Mount Logan’s ability to sustain its recent capital allocation momentum, including the senior notes offering and tender offer, will be closely tied to Satoren’s financial management expertise.

Event summary

• Evogene and Google Cloud are expanding their collaboration, initially announced in October 2024.
• The focus is on integrating AI agents into Evogene’s ChemPass AI™ platform using Google Cloud’s Vertex AI.
• The first phase of the collaboration built a generative AI foundation model for ChemPass AI™.
• The integration aims to accelerate small-molecule discovery and optimization for pharmaceuticals and agriculture.
• Evogene plans to explore making its innovation tools accessible via the Google Cloud Marketplace.

The big picture

What we're watching

Execution Risk

The successful integration of AI agents into ChemPass AI™ is crucial; any delays or technical challenges could impact Evogene’s timelines and partnerships.

Market Adoption

The willingness of pharmaceutical and agricultural companies to adopt Evogene’s AI-driven discovery platform will determine the long-term value of this collaboration.

Competitive Landscape

The emergence of competing AI-driven molecular design platforms could erode Evogene’s competitive advantage if ChemPass AI™ fails to maintain a technological lead.

Event summary

• Milestone Pharmaceuticals appointed David Sandoval as General Counsel and Chief Compliance Officer, effective immediately.
• Sandoval’s appointment coincides with the launch of CARDAMYST™ (etripamil) nasal spray, approved by the FDA on December 12, 2025.
• Sandoval brings over 15 years of experience in legal and compliance within the life sciences sector, particularly in late-stage development and commercialization.
• Prior roles include Senior Vice President, General Counsel, Corporate Compliance Officer and Corporate Secretary at MaxCyte, Inc.

The big picture

What we're watching

Regulatory Headwinds

The effectiveness of Sandoval’s compliance programs will be crucial given CARDAMYST’s novel delivery method and potential for scrutiny regarding patient self-administration.

Execution Risk

Milestone’s ability to scale operations and build infrastructure to support CARDAMYST’s commercialization will be heavily influenced by Sandoval’s legal and compliance expertise.

Litigation Exposure

Given the product's safety profile and potential for adverse events, the frequency and severity of any future litigation will be a key indicator of long-term value.

Event summary

• Cobalt appointed Paul Zymba as Senior Vice President of Customer Success, effective immediately.
• Deepak Dalvi joined Cobalt as Vice President of Product, also effective immediately.
• Zymba brings over 25 years of experience from companies including Veracode, Mendix, GAN Integrity, and Galvanize.
• Dalvi previously held leadership roles at Trellix, Aqua Security, and Lacework.
• Cobalt boasts a Net Promoter Score (NPS) of 9.

The big picture

What we're watching

Execution Risk

The success of these appointments hinges on how effectively Zymba and Dalvi integrate into Cobalt's existing structure and collaborate to drive the stated strategic priorities.

Competitive Landscape

Given Dalvi's experience at multiple competitors, his insights into Cobalt's product roadmap and positioning will be critical in differentiating the platform and maintaining market share.

Enterprise Adoption

The pace at which Cobalt can translate these leadership changes into demonstrable enterprise adoption and expansion will be a key indicator of its ability to capitalize on the growing demand for continuous pentesting.

Event summary

• Mercy St. Louis is the first and only hospital in Missouri to offer Hybrid Coronary Revascularization (HCR).
• HCR combines traditional bypass surgery and stenting, offering a minimally invasive alternative to open-heart surgery.
• Patient Kurtis Cox recovered significantly faster, returning to normal activities within weeks of the procedure.
• Dr. Parth Patel, cardiothoracic surgeon at Mercy St. Louis, leads the HCR program.
• Mercy is a $6 billion health system serving patients across five states.

The big picture

What we're watching

Adoption Rate

The pace at which other Missouri hospitals and health systems adopt HCR will indicate the procedure's perceived value and Mercy's competitive moat.

Reimbursement

How insurers and Medicare/Medicaid reimburse for HCR compared to traditional bypass surgery will be a key driver of its long-term viability.

Expansion

Whether Mercy expands the HCR program to other hospitals within its network will signal confidence in its efficacy and scalability.

Event summary

• IQVIA and the Duke Clinical Research Institute (DCRI) have formed a strategic collaboration focused on accelerating clinical research for obesity and related cardiometabolic conditions.
• The partnership aims to streamline clinical trial processes, from governance and data flow to site-level execution, leveraging DCRI’s operational infrastructure and IQVIA’s global reach and technology.
• IQVIA has previously supported clinical development for all FDA-approved GLP-1 therapies, enrolling over 90,000 patients across more than 120 obesity trials.
• The collaboration will expand access to patient populations across 56 countries and over 3,000 sites.

The big picture

What we're watching

Execution Risk

The success of the collaboration hinges on seamless integration of IQVIA’s technology and DCRI’s operational expertise; friction between the two organizations could impede progress and delay trial timelines.

Regulatory Scrutiny

As obesity drug development intensifies, regulatory bodies like the FDA will likely increase scrutiny of clinical trial design and data integrity, potentially impacting the partnership's ability to expedite approvals.

Competitive Landscape

Other CROs and academic institutions are likely to respond to this partnership, intensifying competition for clinical trial services and potentially driving down margins for all players in the obesity drug development space.

Event summary

• Armis released Armis Centrix™ for Application Security, a new AI-powered platform unifying application security across the software development lifecycle.
• The platform aims to address the growing problem of code-based vulnerabilities, exacerbated by AI-assisted coding practices.
• Armis Centrix™ scans code, dependencies, container images, and configuration files, reducing false alarms by 70% and accelerating MTTR.
• The technology achieved the highest performance in the Public CASTLE Benchmark C@250.
• Armis claims its AI capabilities surpass pattern-matching solutions, offering highly accurate vulnerability detection across numerous languages.

The big picture

What we're watching

Adoption Rate

The success of Armis Centrix™ hinges on rapid adoption within development teams, which will depend on ease of integration and demonstrable ROI beyond security metrics.

AI Accuracy

Continued validation of Armis’ AI’s accuracy and ability to detect novel vulnerabilities will be crucial to maintaining a competitive advantage in the evolving threat landscape.

Competitive Response

Existing application security vendors will likely respond with competing AI-powered features, potentially eroding Armis’s market share if they fail to innovate continuously.

Event summary

• BioRestorative Therapies has completed patient enrollment in its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease.
• The trial enrolled 99 participants in a randomized, double-blind, sham-controlled design across 15 U.S. clinical sites.
• The study is described as the largest FDA-authorized Phase 2 cell therapy trial for chronic lumbar disc disease.
• The trial's primary endpoints focus on safety (adverse events) and efficacy (ODI and VAS improvements).

The big picture

What we're watching

Regulatory Pathway

The FDA's feedback on the trial data will be critical in determining the likelihood of Phase 3 approval and a Biologics License Application (BLA) submission, and the company's stated confidence should be viewed with caution.

Efficacy Data

The actual efficacy results, particularly the ODI and VAS improvements, will dictate investor sentiment and the potential for commercial success, given the high bar for therapeutic intervention in chronic back pain.

Execution Risk

The accelerated site productivity observed in the last six months needs to be sustained throughout the trial and into any subsequent Phase 3 studies to maintain timelines and manage costs.

Event summary

• HydroGraph Clean Power Inc. has added Hubron International to its Compounding Partner Program.
• Hubron International, a UK-based leader in black masterbatch and conductive polymer compounds, has over 90 years of experience and exports over 85% of its production.
• The partnership aims to expand the commercial adoption of HydroGraph’s Fractal Graphene™ in thermoplastics.
• Hubron’s capabilities include twin-screw extrusion, Buss kneaders, and specialized processing lines, along with experience in nanomaterial compounding.

The big picture

What we're watching

Market Penetration

The success of this partnership hinges on Hubron’s ability to effectively integrate Fractal Graphene™ into existing product lines and reach new customers within its established distribution network.

Scalability

HydroGraph’s ability to maintain consistent graphene quality and supply volume will be crucial to supporting Hubron’s manufacturing capabilities and fulfilling anticipated demand.

Competitive Landscape

The partnership's impact will depend on how effectively HydroGraph and Hubron can differentiate their graphene-enhanced materials from competing solutions utilizing alternative nanomaterials or traditional compounding methods.

Event summary

• INmune Bio submitted a pre-submission package for CORDStrom™ to the UK MHRA for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
• The pre-submission process aims to streamline the full Marketing Authorization Application (MAA) and accelerate potential approval.
• Commercial-scale manufacturing runs at the CGT Catapult facility have confirmed product readiness.
• INmune anticipates filing a full MAA in mid-summer 2026, followed by US submissions in Q4 2026.
• The reauthorization of the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029 could provide a significant incentive for US approval.

The big picture

What we're watching

Regulatory Response

The MHRA’s feedback on the pre-submission package will be critical in shaping the timeline and potential requirements for full approval, and will reveal the agency’s appetite for novel cell therapies in rare diseases.

Manufacturing Scale

While initial manufacturing runs have been successful, sustained, large-scale production of CORDStrom™ will be essential to meet potential demand and avoid supply chain bottlenecks post-approval.

PRV Utilization

INmune’s ability to secure and utilize the Rare Pediatric Disease Priority Review Voucher will significantly impact the speed of US approval and the company’s overall valuation.

Event summary

• DoubleLine's Robert Cohen and Chris Stegemann published a paper, 'Volatility Laundering in Private Credit,' highlighting structural risks within the private credit market.
• The paper argues that private credit companies avoiding public markets are often riskier, seeking flexibility through one-on-one borrower relationships.
• DoubleLine cautions that marketing strategies in private credit may misrepresent volatility, particularly regarding the 'illiquidity premium'.
• Robert Cohen, Director of Global Developed Credit, and Chris Stegemann, Manager of Client Portfolio Management, authored the report.

The big picture

What we're watching

Investor Behavior

How investor recalibration of expectations regarding private versus public credit will impact capital flows into the private credit space remains to be seen.

Risk Migration

Whether the trend of riskier companies migrating to private credit will continue as public markets tighten and economic conditions evolve warrants close monitoring.

Marketing Scrutiny

The pace at which regulatory bodies and institutional investors scrutinize private credit marketing practices and transparency will likely influence the sector's future growth.

Event summary

• Robo.ai (NASDAQ: AIIO) and DaBoss.AI have established a 51/49 joint venture in the UAE.
• Robo.ai will control the JV and consolidate its financial results.
• The JV aims to create a distributed embodied intelligence data acquisition and annotation center.
• Commercial operations are expected to begin within 90 days.
• The venture will utilize a 'dual-engine' data acquisition methodology combining robotic terminals and VR/wearable devices.

The big picture

What we're watching

Geopolitical Risk

The UAE's strategic position offers compliance advantages, but also introduces geopolitical risks that could impact operations and data security.

Execution Risk

The rapid 90-day timeline for deployment and commercialization presents significant execution risk, particularly given the complexity of distributed data acquisition infrastructure.

Competitive Landscape

The emergence of a specialized embodied AI data platform will likely attract competitors, potentially driving down pricing and margins within the nascent market.

Event summary

• ECARX completed a $100 million convertible notes offering, fully subscribed as of February 9, 2026.
• The offering was completed in three tranches: $35 million on November 14, 2025; $25 million on November 26, 2025; and $40 million on February 9, 2026.
• The notes have an initial conversion price of $2.62, and ECARX used the proceeds to refinance $65 million of previous convertible notes.
• The transaction follows a $45.6 million strategic investment from Geely in January 2026.

The big picture

What we're watching

Conversion Risk

The conversion price of the notes, while seemingly reasonable, will be a key factor in ECARX’s future equity dilution and will be sensitive to the company’s stock performance.

Geely Influence

The significant investment from Geely warrants scrutiny of any potential strategic alignment or influence on ECARX’s decision-making and product roadmap.

Project Execution

ECARX’s ability to successfully deliver on the two major projects from Volkswagen Group will be critical to justifying the capital raised and achieving its growth targets.

Event summary

• FPX Nickel has entered the public comment period for its Baptiste Nickel Project, following acceptance of the Initial Project Description in January 2026.
• The public comment period, jointly run by the BC EAO and IAAC, will continue until March 9, 2026.
• The Baptiste Project involves a large-scale discovery of awaruite, a sulphur-free nickel-iron alloy, located in central British Columbia.
• Approximately US$55 million has been invested in the project since 2010.
• The Province of British Columbia has prioritized the Baptiste Nickel Project through its Critical Minerals Office concierge service.

The big picture

What we're watching

Community Relations

The feedback received during the public comment period will be crucial in shaping the project's design and operation, potentially impacting timelines and costs.

Regulatory Risk

The outcome of the environmental assessment process remains uncertain, and any significant pushback from regulators or communities could delay or alter the project's scope.

Carbon Intensity

FPX's claim of low-carbon nickel production hinges on the ability to connect to the BC Hydro grid and avoid traditional smelting processes; disruptions to either could undermine this advantage.

Event summary

• Sands China and Las Vegas Sands senior management led a volunteer activity on February 3, 2026, involving approximately 300 participants.
• The initiative resulted in the assembly of 2,000 Lunar New Year gift packs containing over 20,000 staple foods and essential items.
• Sands China's Entrepreneurship Recruitment Programme for Rua das Estalagens supports local SMEs.
• The Sands Cares Ambassador program has amassed over 360,000 volunteer hours to date, with 4,000 team members participating.

The big picture

What we're watching

Tourism Dependence

The continued reliance on tourism for Sands China's revenue stream makes community initiatives a key tool for maintaining goodwill and social license to operate, especially as Macau seeks to diversify its economy.

Program Sustainability

The long-term financial commitment required to sustain the Sands Cares program and its associated volunteer hours will be a key indicator of Sands China’s dedication to CSR beyond symbolic gestures.

SME Impact

The success of the Entrepreneurship Recruitment Programme for Rua das Estalagens will be a test of Sands China’s ability to meaningfully contribute to the economic development of local communities.

Event summary

• Bread Financial reported a Net Principal Loss Rate of 7.1% for January 2026, down from 7.8% in January 2025.
• The company's average credit card and other loans remained relatively stable year-over-year, decreasing by only 2% to $18.531 billion.
• January 2026 delinquency rates also improved slightly, falling to 5.9% from 6.1% the prior year.
• Bread Financial's end-of-period credit card and other loans totaled $18,386 million, a slight increase from $18,366 million the previous year.

The big picture

What we're watching

Macroeconomic Impact

The sustainability of these loss rate improvements will depend heavily on the broader economic environment and consumer spending patterns, particularly given ongoing recessionary concerns.

Competitive Landscape

Bread Financial's ability to maintain its position will be challenged by the increasing presence of fintech companies and the evolution of alternative payment solutions.

Regulatory Scrutiny

Potential regulatory changes regarding credit card interest rates, fees, and interchange could significantly impact Bread Financial's profitability and business model.

Event summary

• Emerge Commerce reported preliminary Q4 2025 revenue of $7.0M, up 32% year-over-year from $5.3M.
• Full-year 2025 revenue reached $27.6M, a 43% increase compared to $19.3M in 2024.
• The company achieved positive Adjusted EBITDA of $200K-$250K in Q4 and $1.5M for the full year, reversing a $473K loss in 2024.
• Emerge's cash position grew to $4.1M as of December 31, 2025, from $3.1M a year prior.
• CEO Ghassan Halazon stated the company met its three core operational objectives for 2025: revenue growth, positive Adjusted EBITDA, and positive cash flow.

The big picture

What we're watching

Seasonality

The CEO noted Q4's seasonal impact on the T2G business, suggesting potential volatility in future quarterly results and requiring careful monitoring of performance during non-peak periods.

B2B Sales

Record B2B sales contributed significantly to the strong holiday season performance; the sustainability of this growth and its impact on margins warrants close observation.

Audit Confirmation

The preliminary results are subject to change upon audit; the magnitude of any adjustments in late April will be a key indicator of the accuracy of current projections.

Event summary

• ReposiTrak (NYSE: TRAK) announced a patent-pending system for automated error detection and correction of food traceability data.
• The system addresses an industry-wide problem of up to 40% error rates in traceability records, despite technical compliance with standards.
• The technology normalizes data from various formats (EDI, CSV, XLSX, XML, JSON, API feeds) and uses a hybrid AI/rule-based engine for correction.
• ReposiTrak’s system generates and ranks correction candidates, applying them automatically or routing them for human review with audit trails.
• Randy Fields, Chairman & CEO, stated the technology is built on years of experience operating traceability networks at scale.

The big picture

What we're watching

Adoption Rate

The success of this technology hinges on ReposiTrak’s ability to drive adoption among its existing client base and attract new customers, particularly given the complexity of integrating with diverse data formats.

Patent Defense

Given the competitive landscape in supply chain software, ReposiTrak will need to vigorously defend its patent to maintain a differentiated offering and prevent competitors from replicating its error correction capabilities.

AI Accuracy

The effectiveness of the AI-driven inference component will be critical; inaccuracies in automated corrections could erode trust and necessitate increased human oversight, negating some of the efficiency gains.